Direct interaction of a ligand for the erbB2 oncogene product with the EGF receptor and p185erbB2

Ruth Lupu, Ramon Colomer, Gerhard Zugmaier, Jay Sarup, Michael Shepard, Dennis Slamon, Marc E. Lippman

Research output: Contribution to journalArticlepeer-review

236 Scopus citations


The erbB2 oncogene encodes a 185-kilodalton transmembrane protein whose sequence is similar to the epidermal growth factor receptor (EGFR). A 30-kilodalton factor (gp30) secreted from MDA-MB-231 human breast cancer cells was shown to be a ligand for p185erbB2. An antibody to EGFR abolished the tyrosine phosphorylation induced by EGF and transforming growth factor-α (TGF-α) but only partially blocked that produced by gp30 in SK-BR-3 breast cancer cells. In two cell lines that overexpress erbB2 but do not express EGFR (MDA-MB-453 breast cancer cells and a Chinese hamster ovary cell line that had been transfected with erbB2), phosphorylation of p185 erbB2 was induced only by gp30. The gp30 specifically inhibited the growth of cells that overexpressed p185erbB2. An antibody to EGFR had no effect on the inhibition of SK-BR-3 cell colony formation obtained with gp30. Thus, it appeared that gp30 interacted directly with the EGFR and erbB2. Direct binding of gp30 to p185erbB2 was confirmed by binding competition experiments, where gp30 was found to displace the p185 erbB2 binding of a specific antibody to p185erbB2. The evidence described here suggests that gp30 is a ligand for p185erbB2.

Original languageEnglish (US)
Pages (from-to)1552-1555
Number of pages4
Issue number4976
StatePublished - 1990

ASJC Scopus subject areas

  • General


Dive into the research topics of 'Direct interaction of a ligand for the erbB2 oncogene product with the EGF receptor and p185erbB2'. Together they form a unique fingerprint.

Cite this